The US-based biopharmaceutical company has … All rights reserved. CURRENT PRICE ... Health Care. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestina l (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. There are currently 888,727 Albireo Pharma shares held short by investors – that's known as Albireo Pharma's "short interest". Equal Opportunity Employer. Albireo Pharma, Inc. (NASDAQ: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the initiation of its global Phase 3 … There are currently no approved drug therapies for Progressive Familial Intrahepatic Cholestasis (PFIC). Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. Business activities of this company are managed together by 4 persons, who are responsible for correct companys operations on the market. Biotech & Pharma. The incorporation date of this company is on 16th May 2017 and its headquarters can be found at 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON, MA, 02109. Get the latest Albireo Pharma, Inc. ALBO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Get the latest Albireo Pharma, Inc. ALBO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Albireo Pharma has submitted odevixibat to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), seeking approval for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC). State Street Corp’s holdings in Albireo Pharma were worth $7,463,000 as of its most recent filing with […] Website www.albireopharma.com. Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. Dedicated to the development of novel bile acid modulators to relieve the pain and suffering of people living with orphan liver diseases. FOUNDED. Click here to find out why we have been named a Best Place to Work in Boston for 2 years in a Row! Find the latest press releases from Albireo Pharma, Inc. Common Stock (ALBO) at Nasdaq.com. Health Care. Biotech & Pharma. . Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. 1-857-254-5555. Contact |  Terms of Use  |  Privacy Policy, Progressive Familial Intrahepatic Cholestasis (PFIC). Item 8.01 Other Events. 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON, MA, 02109. They are RONALD H.W. Chief Human Resources Officer at Albireo Pharma, Inc. Our programs are designed to target and enable normal bile acid level modulation and treat diseases and disorders associated with irregularities in bile acid biology. 12/08/2003. Albireo Pharma serves patients in the United States. INDUSTRY. Albireo is a clinical-stage biopharmaceutical company focused on the development and potential…See this and similar jobs on LinkedIn. See insights on Albireo Pharma including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. The firm owned 223,648 shares of the biopharmaceutical company’s stock after selling 2,976 shares during the quarter. Albireo Pharma Overview: Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Detailed company description & address for Albireo Pharma Inc.. Dow Jones, a News Corp company. View Albireo Pharma, Inc. ALBO investment & stock information. We are taking appropriate precautions to protect the safety and health of those around us, while ensuring that patients participating in our studies have continued access to Mirum’s investigational treatments. Shorting Albireo Pharma shares. Albireo Pharma is headquartered in Boston, MA and has 2 office locations across 2 countries. We are developing odevixibat initially to treat patients with PFIC, a rare genetic liver disease. Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Company is located in the register under the national Company number 1239223. To address these ongoing needs, we are working closely with healthcare providers, our third-party manufacturers, and our study service providers to minimize disruption while supporting our communities’ efforts to slow the spread of the virus. ALBIREO PHARMA, INC. is a business legal entity registered in compliance with the national legislation of the State of Connecticut under the legal form of Stock. ©2017 Ct-registry.com. ADDRESS. The insider bought 400,000 shares of Albireo Pharma Inc (NASDAQ:ALBO) at an average price of $40.00. State Street Corp lessened its holdings in shares of Albireo Pharma, Inc. (NASDAQ:ALBO) by 1.3% in the 3rd quarter, HoldingsChannel reports. Detailed Estimate. On December 8, 2020, Albireo Pharma, Inc. issued a press release announcing that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of odevixibat for the treatment of patients with progressive familial … Albireo Pharma, Inc. is an equal opportunity employer and does not discriminate against any applicant because of race, creed, color, age, national origin, ancestry, religion, gender, sexual orientation, disability, genetic information, veteran status, military status, application for military service or any other class protected by state or federal law. State Street Corp lessened its holdings in shares of Albireo Pharma, Inc. (NASDAQ:ALBO) by 1.3% in the 3rd quarter, HoldingsChannel reports. On February 3, 2020, Albireo Pharma, Inc. (the “Company”) issued a press release (the “Closing Press Release”) announcing that it had closed its previously announced public offering of 2,190,750 shares of its common stock at a public offering price of $21.00 per share, which includes the exercise in full of the underwriters’ option to purchase additional shares. Company is located in the register under the national Company number 1239223. For more information, read Albireo's Corporate Backgrounder. Media Contact: Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com About Albireo Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Detailed company description & address for Albireo Pharma Inc.. Dow Jones, a News Corp company. Albireo Pharma has 55 employees across 2 locations and $9.64 M in annual revenue in FY 2019. Get the latest Detailed Estimate from Zacks Investment Research. Form SC 13G filed by Albireo Pharma, Inc. with the security and exchange commission. 10 Post Office Square Suite 502 South Boston, MA 02109 United States. Albireo Pharma serves patients in the United States. SUB-INDUSTRY. You can contact Albireo 's Board of Directors to provide comments, to report concerns, or to ask a question, at the following address. State Street Corp’s holdings in Albireo Pharma were worth $7,463,000 as of its most recent filing with […] ALBIREO PHARMA, INC. is a business legal entity registered in compliance with the national legislation of the State of Connecticut under the legal form of Stock. Albireo Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille SyndromeRead the full press release. Phone. Wedbush analyst L. Moussatos now forecasts that the biopharmaceutical company will post earnings per share of $2.01 Phone: (857) 254-5555. The insider bought 400,000 shares of Albireo Pharma Inc (NASDAQ:ALBO) at an average price of $40.00. 12/08/2003. Medical Information. Greater Boston. There are a few different ways that this level of interest in shorting Albireo Pharma shares can be evaluated. The firm owned 223,648 shares of the biopharmaceutical company’s stock after selling 2,976 shares during the quarter. Address. View Albireo Pharma, Inc. ALBO investment & stock information. Find out the direct holders, institutional holders and mutual fund holders for Albireo Pharma, Inc. (ALBO). A JOYFUL PATH WITHIN OUR NEIGHBORHOOD DAYCARE CENTER LLC, KULLAVIKSVAGEN 137, SE 429, 33, KULLAVIK, SWE, 50 WESTON STREET, HARTFORD, CT, 06120-1537. FOUNDED. You may submit your concern anonymously or confidentially by postal mail. Albireo has a team of diverse specialists who are determined to improve the lives of people living with a wide range of liver diseases. See the full list at Craft. Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. 3 Ethel Road, Suite 300 Edison, New Jersey 08817 Sales & Service: (732) 512-9100 Manhattan, NY – Office. (857) 378-2035. medinfo@albireopharma.com. SUB-INDUSTRY. 10 … Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. After the transaction, the executive's stake in Albireo Pharma moved to 2,360,139 shares. Albireo Pharma Overview: Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Albireo Pharma, Inc. 10 Post Office Square. On December 8, 2020, Albireo Pharma, Inc. issued a press release announcing that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of odevixibat for the treatment of patients with progressive familial intrahepatic … Health Care. Our goal is to change that. 10 Post … April Eldred (Venables) April Eldred (Venables) This figure is 23.4% down from 1.2 million last month. Suite 1000. Actually the company´s status is Active. COOPER as principal with the seat at 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON, MA, 02109 , JAN P. MATTSSON, PH.D. as principal with the seat at 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON, MA, 02109 , THOMAS A. SHEA as principal with the seat at 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON, MA, 02109 , CORPORATION SERVICE COMPANY as registered agent with the seat at 50 WESTON STREET, HARTFORD, CT, 06120-1537 . Albireo Pharma serves patients in the United States. Boston, MA 02109. ALBO: Albireo Pharma, Inc. Albireo Pharma, Inc. (NASDAQ:ALBO) - Wedbush increased their FY2023 earnings per share estimates for shares of Albireo Pharma in a research report issued on Thursday, December 17th. 6 East 46th Street Suites 300/301 Item 8.01 Other Events. NEW YORK REGION Edison, NJ – Headquarters. View Albireo Pharma Inc stock profile overview, company profile includes total employees, company financial synopsis, address and web links. All data on website has informational character only and are taken from publicly available sources. At Mirum Pharmaceuticals, the health and welfare of our patients and employees is a top priority. Albireo Pharma, Inc. Common Stock (ALBO) Revenue EPS : Previous 3 Years Next 3 Years. We leverage our expertise in bile acid modulation with the goal of bringing potentially transformative medicines to patients. INDUSTRY. CURRENT PRICE ... Health Care. ADDRESS. Corporate Secretary Albireo 10 Post Office Square Suite 1000 Boston, MA 02109 United States. The incorporation date of this company is on 16th May 2017 and its headquarters can be found at 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON, MA, 02109. Find out more. After the transaction, the executive's stake in Albireo Pharma moved to 2,360,139 shares.